Area Development News Desk (01/19/2009)
PDS Biotechnology Corporation, a developer of nanotechnology-based biotechnology products, will relocate its corporate headquarters and laboratory facilities to Indianapolis, Indiana, according to the Indiana governor's office. The company, currently based in Cincinnati, Ohio, has not yet chosen a specific location in the city, but plans to begin clinical trials within the next 18 months on its nanotechnology-based therapy that stimulates the immune system to fight infections and cancers. "PDS Biotechnology chose to locate the company in Indiana over other competing states based on several important factors, including the presence of top-rated universities, a world-class nanotechnology center, and the solid and rapidly growing biotechnology infrastructure," says Dr. Frank Bedu-Addo, the company's president and chief executive. Financial incentives offered to PDS Biotechnology include a $2 million grant from the state.
All contents copyright 2024 Halcyon Business Publications, Inc.